| Drug Name | ***0007 |
| Description |
***0007 is a BCMA/CD19 dual-target CAR-T cell immunotherapy in early clinical development for the treatment of relapsed or refractory multiple myeloma. |
| Target | BCMA; CD19 |
| Drug Modality | CAR T cells |
| Indication | Multiple Myeloma |
| Product Category | Cancer Immunotherapy |
| Mechanism of Action | Targeting B-Lymphocyte Antigen CD19 and B-cell Maturation Protein (BCMA) |
| Status | Phase I |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial cross-border BD consulting service to encompass segments in equity investment and project incubation.
 |
Protheragen Inc. |
 |
Quick Links |
